CONMED Stock Price, News & Analysis (NYSE:CNMD) $109.36 +0.91 (+0.84%) (As of 10:09 AM ET) Add Compare Share Share Today's Range$108.68▼$109.6550-Day Range$91.30▼$111.5152-Week Range$82.97▼$138.47Volume15,386 shsAverage Volume375,193 shsMarket Capitalization$3.36 billionP/E Ratio59.11Dividend Yield0.73%Price Target$126.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability CONMED MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside16.3% Upside$126.17 Price TargetShort InterestBearish15.35% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainability-0.74Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$337,488 Sold Last QuarterProj. Earnings Growth26.29%From $3.50 to $4.42 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector459th out of 948 stocksMedical Devices Industry10th out of 17 stocks 2.4 Analyst's Opinion Consensus RatingCONMED has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $126.17, CONMED has a forecasted upside of 16.3% from its current price of $108.46.Amount of Analyst CoverageCONMED has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.35% of the outstanding shares of CONMED have been sold short.Short Interest Ratio / Days to CoverCONMED has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in CONMED has recently increased by 7.76%, indicating that investor sentiment is decreasing significantly. Previous Next 1.7 Dividend Strength Dividend YieldCONMED has a dividend yield of 0.73%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthCONMED does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of CONMED is 43.24%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, CONMED will have a dividend payout ratio of 18.10% next year. This indicates that CONMED will be able to sustain or increase its dividend. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCONMED has received a 64.86% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Surgical instruments", "Medical technology engineering", and "Training for medical professionals" products. See details.Environmental SustainabilityThe Environmental Impact score for CONMED is -0.74. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for CONMED this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added CONMED to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CONMED insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $337,488.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of CONMED is held by insiders. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for CONMED are expected to grow by 26.29% in the coming year, from $3.50 to $4.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CONMED is 58.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.07.Price to Earnings Ratio vs. SectorThe P/E ratio of CONMED is 58.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.37.Price to Earnings Growth RatioCONMED has a PEG Ratio of 1.10. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCONMED has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CONMED Stock (NYSE:CNMD)CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.Read More CNMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNMD Stock News HeadlinesDecember 5, 2023 | msn.comCONMED declares $0.20 dividendNovember 28, 2023 | americanbankingnews.comAnalyzing CONMED (NYSE:CNMD) and NeurAxis (NASDAQ:NRXS)December 6, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 24, 2023 | finance.yahoo.comConmed (CNMD) Up 14.3% Since Last Earnings Report: Can It Continue?November 22, 2023 | finance.yahoo.comIs There An Opportunity With CONMED Corporation's (NYSE:CNMD) 44% Undervaluation?November 13, 2023 | finance.yahoo.comCONMED Corporation to Participate in a Fireside Chat at the Piper Sandler Healthcare ConferenceOctober 31, 2023 | finance.yahoo.comCONMED Corporation to Participate in Fireside Chats at Two Investor Conferences on November 14-15October 30, 2023 | finance.yahoo.comThe Conmed Corp (CNMD) Company: A Short SWOT AnalysisDecember 6, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 28, 2023 | seekingalpha.comConmed: Sector Derating And A New Competitive Threat Shouldn't Overshadow A Solid Core BusinessOctober 27, 2023 | msn.comPiper Sandler Maintains Conmed (CNMD) Overweight RecommendationOctober 27, 2023 | finance.yahoo.comCONMED Corporation (NYSE:CNMD) Q3 2023 Earnings Call TranscriptOctober 27, 2023 | markets.businessinsider.comHold Rating on Conmed: Balancing Double-Digit Revenue Growth and Market ChallengesOctober 27, 2023 | nasdaq.comStifel Maintains Conmed (CNMD) Buy RecommendationOctober 27, 2023 | nasdaq.comNeedham Maintains Conmed (CNMD) Buy RecommendationOctober 26, 2023 | markets.businessinsider.comHold Rating on Conmed Amid Strong Q3 Performance and Anticipated Supply ConstraintsOctober 26, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Conmed (CNMD), Edwards Lifesciences (EW) and Prothena (PRTA)October 26, 2023 | finance.yahoo.comCNMD or ALGN: Which Is the Better Value Stock Right Now?October 25, 2023 | markets.businessinsider.comConmed Corp. Q3 Profit Decreases, but beats estimatesOctober 25, 2023 | finance.yahoo.comConmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to SayOctober 25, 2023 | sfgate.comConmed: Q3 Earnings SnapshotOctober 25, 2023 | finance.yahoo.comCONMED Corporation Announces Third Quarter 2023 Financial ResultsOctober 25, 2023 | finance.yahoo.comConmed Corp (CNMD) Announces Q3 2023 Financial ResultsOctober 25, 2023 | seekingalpha.comCONMED Corporation 2023 Q3 - Results - Earnings Call PresentationOctober 19, 2023 | finance.yahoo.comAre Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?October 9, 2023 | finance.yahoo.comThose who invested in CONMED (NYSE:CNMD) five years ago are up 40%October 4, 2023 | finance.yahoo.comCONMED Corporation to Announce Third Quarter 2023 Financial Results on October 25, 2023See More Headlines Receive CNMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 10/5 Dividend9/14/2023Dividend Payable10/05/2023Last Earnings10/25/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/01/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolNYSE:CNMD CUSIPN/A CIK816956 Webwww.conmed.com Phone(727) 392-6464Fax315-797-0321Employees4,100Year FoundedN/APrice Target and Rating Average Stock Price Target$126.17 High Stock Price Target$141.00 Low Stock Price Target$107.00 Potential Upside/Downside+16.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$1.85 Trailing P/E Ratio58.63 Forward P/E Ratio30.99 P/E Growth1.1Net Income$-80,580,000.00 Net Margins4.96% Pretax Margin2.53% Return on Equity11.46% Return on Assets3.80% Debt Debt-to-Equity Ratio1.18 Current Ratio1.66 Quick Ratio0.80 Sales & Book Value Annual Sales$1.05 billion Price / Sales3.19 Cash Flow$5.17 per share Price / Cash Flow20.96 Book Value$24.46 per share Price / Book4.43Miscellaneous Outstanding Shares30,750,000Free Float28,415,000Market Cap$3.34 billion OptionableOptionable Beta1.36 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Curt R. Hartman (Age 59)Chairman of the Board, CEO & President Comp: $1.5MMr. Todd W. Garner (Age 54)Executive VP & CFO Comp: $783.48kMs. Heather L. Cohen (Age 50)Executive VP and Chief Human Resources & Legal Officer Comp: $561.01kMr. Patrick J. Beyer (Age 57)President of International & Global Orthopedics Comp: $1.22MMr. Stanley W. Peters III (Age 48)President of Advanced Surgical & Advanced Endoscopic Technologies Comp: $648.12kMr. Peter K. Shagory (Age 54)Executive Vice President of Strategy & Corporate Development Ms. Shanna L. Cotti-Osmanski (Age 46)Executive VP of Information Technology & CIO Mr. Brent Lalomia (Age 48)Executive Vice President of Quality Assurance & Regulatory Affairs Mr. John Ferrell (Age 55)Executive Vice President of Human Resources Mr. Daniel S. Jonas Esq. (Age 59)Special Counsel & Corporate Secretary Comp: $646.48kMore ExecutivesKey CompetitorsInari MedicalNASDAQ:NARIPROCEPT BioRoboticsNASDAQ:PRCTNovoCureNASDAQ:NVCRUFP TechnologiesNASDAQ:UFPTAdaptHealthNASDAQ:AHCOView All CompetitorsInsiders & InstitutionsPublic Sector Pension Investment BoardSold 16,277 shares on 11/22/2023Ownership: 0.124%Graham Capital Management L.P.Bought 2,058 shares on 11/22/2023Ownership: 0.007%Walleye Capital LLCBought 56,427 shares on 11/21/2023Ownership: 0.183%Walleye Trading LLCBought 1,800 shares on 11/21/2023Ownership: 0.000%Creative PlanningSold 295 shares on 11/16/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions CNMD Stock Analysis - Frequently Asked Questions Should I buy or sell CONMED stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CNMD shares. View CNMD analyst ratings or view top-rated stocks. What is CONMED's stock price target for 2024? 6 brokers have issued twelve-month target prices for CONMED's stock. Their CNMD share price targets range from $107.00 to $141.00. On average, they expect the company's stock price to reach $126.17 in the next year. This suggests a possible upside of 16.3% from the stock's current price. View analysts price targets for CNMD or view top-rated stocks among Wall Street analysts. How have CNMD shares performed in 2023? CONMED's stock was trading at $88.64 on January 1st, 2023. Since then, CNMD shares have increased by 22.4% and is now trading at $108.46. View the best growth stocks for 2023 here. Are investors shorting CONMED? CONMED saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 4,720,000 shares, an increase of 7.8% from the October 31st total of 4,380,000 shares. Based on an average daily volume of 359,400 shares, the short-interest ratio is presently 13.1 days. View CONMED's Short Interest. When is CONMED's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024. View our CNMD earnings forecast. How were CONMED's earnings last quarter? CONMED Co. (NYSE:CNMD) posted its earnings results on Wednesday, October, 25th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.07. The company had revenue of $304.58 million for the quarter, compared to analysts' expectations of $301.22 million. CONMED had a trailing twelve-month return on equity of 11.46% and a net margin of 4.96%. How often does CONMED pay dividends? What is the dividend yield for CONMED? CONMED declared a quarterly dividend on Thursday, August 10th. Shareholders of record on Friday, September 15th will be given a dividend of $0.20 per share on Thursday, October 5th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date is Thursday, September 14th. Read our dividend analysis for CNMD. Is CONMED a good dividend stock? CONMED (NYSE:CNMD) pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.73%. The dividend payout ratio is 43.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CNMD will have a dividend payout ratio of 18.10% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for CNMD. What ETFs hold CONMED's stock? ETFs with the largest weight of CONMED (NYSE:CNMD) stock in their portfolio include Small Cap US Equity Select ETF (RNSC), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Xtrackers S&P SmallCap 600 ESG ETF (SMLE), SPDR S&P SmallCap 600 ESG ETF (ESIX), SPDR S&P 600 Small Cap ETF (SLY), Vanguard S&P Small-Cap 600 Value ETF (VIOV) and Vanguard S&P Small-Cap 600 ETF (VIOO). What guidance has CONMED issued on next quarter's earnings? CONMED updated its FY23 earnings guidance on Wednesday, October, 25th. The company provided EPS guidance of $3.45-3.55 for the period, compared to the consensus estimate of $3.48. The company issued revenue guidance of $1.24-1.26 billion, compared to the consensus revenue estimate of $1.25 billion. Who are CONMED's major shareholders? CONMED's stock is owned by many different retail and institutional investors. Top institutional investors include Earnest Partners LLC (7.37%), Loomis Sayles & Co. L P (2.57%), Principal Financial Group Inc. (1.99%), Bank of New York Mellon Corp (1.39%), Jennison Associates LLC (1.19%) and Northern Trust Corp (1.10%). Insiders that own company stock include Brian Concannon, Curt R Hartman, Daniel S Jonas, John D Ferrell, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III, Todd W Garner and Todd W Garner. View institutional ownership trends. How do I buy shares of CONMED? Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:CNMD) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CONMED Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.